We have collected information about Intravenous Delivery Of A Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus for you. Follow the links to find out details on Intravenous Delivery Of A Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus.
https://www.nature.com/articles/nature10358
Aug 31, 2011 · JX-594 is an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells harbouring activation of the epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis and anticancer immunity 1. Here we show in a clinical trial that JX-594 selectively infects,...Author: Caroline J. Breitbach, James Burke, Derek Jonker, Derek Jonker, Joe Stephenson, Andrew R. Haas, Laur...
https://www.ncbi.nlm.nih.gov/pubmed/21886163
Aug 31, 2011 · JX-594 is an oncolytic poxvirus engineered for replication, transgene expression and amplification in cancer cells harbouring activation of the epidermal growth factor receptor (EGFR)/Ras pathway, followed by cell lysis and anticancer immunity.Author: Caroline J. Breitbach, James Burke, Derek Jonker, Derek Jonker, Joe Stephenson, Andrew R. Haas, Laur...
https://www.nature.com/articles/nature10358?error=cookies_not_supported&code=21cfcbff-87d5-4921-8ce6-c8c77ce05fef
We hypothesized that a poxvirus, which evolved for blood-borne systemic spread in mammals, could be engineered for cancer-selective replication and used as a vehicle for the intravenous delivery ...Author: Caroline J. Breitbach, James Burke, Derek Jonker, Derek Jonker, Joe Stephenson, Andrew R. Haas, Laur...
https://www.researchgate.net/profile/Jorge_Nieva/publication/51610875_Intravenous_delivery_of_a_multi-mechanistic_cancer-targeted_oncolytic_poxvirus_in_humans/links/53d90e1b0cf2e38c6331e268.pdf
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans Caroline J. Breitbach 1 , James Burke 2 {, Derek Jonker 3,4 , Joe Stephenson 5 , Andrew R. Haas 6 , Laura Q ...Author: Caroline J. Breitbach, James Burke, Derek Jonker, Derek Jonker, Joe Stephenson, Andrew R. Haas, Laur...
https://www.researchgate.net/publication/51610875_Intravenous_delivery_of_a_multi-mechanistic_cancer-targeted_oncolytic_poxvirus_in_humans
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans Article (PDF Available) in Nature 477(7362):99-102 · September 2011 with 609 Reads How we measure 'reads'
https://www.academia.edu/15507696/Intravenous_delivery_of_a_multi-mechanistic_cancer-targeted_oncolytic_poxvirus_in_humans
The efficacy and safety of biological molecules in cancer therapy, such as peptides and small interfering RNAs (siRNAs), could be markedly increased if high concentrations could be achieved and amplified selectively in tumour tissues versus normal
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084676/
Sep 09, 2016 · In contrast to gene therapy where a virus is used as a mere carrier for transgene delivery, oncolytic virus therapy uses the virus itself as an active drug reagent. The concept of oncolytic virus therapy has existed for some time (Fig. (Fig.1). 1).Author: Hiroshi Fukuhara, Yasushi Ino, Tomoki Todo
https://onlinelibrary.wiley.com/doi/full/10.1111/cas.13027
An oncolytic virus is defined as a genetically engineered or naturally occurring virus that can selectively replicate in and kill cancer cells without harming the normal tissues. In contrast to gene therapy where a virus is used as a mere carrier for transgene delivery, oncolytic virus therapy uses the virus itself as an active drug reagent.Author: Hiroshi Fukuhara, Yasushi Ino, Tomoki Todo
https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(20)30126-X
In the present study we have identified transient pharmacological inhibition of the leukocyte-enriched phosphoinositide 3-kinase δ (PI3Kδ) as a novel mechanism to potentiate intravenous delivery of oncolytic VV to tumors.Author: Mark S. Ferguson, Louisa S. Chard Dunmall, Rathi Gangeswaran, Giulia Marelli, James R. Tysome, James...
https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)30280-5
Sep 01, 2015 · Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. Se Hoon Park ... Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. ... Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature ...Author: Se Hoon Park, Caroline J Breitbach, Jeeyun Lee, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Anne Moon, ...
Searching for Intravenous Delivery Of A Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus?
You can just click the links above. The data is collected for you.
